Breaking News

Tweet TWEET

Price Movements, Leadership Appointments, Patient Enrollments and Supply Agreements - Research Report on Santarus, Hologic,

   Price Movements, Leadership Appointments, Patient Enrollments and Supply
  Agreements - Research Report on Santarus, Hologic, Brookdale, Idenix, and
                                    Biodel

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 20, 2013

NEW YORK, December 20, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Santarus,
Inc. (NASDAQ: SNTS), Hologic Inc. (NASDAQ: HOLX), Brookdale Senior Living Inc.
(NYSE: BKD), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), and Biodel Inc.
(NASDAQ: BIOD). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Santarus, Inc. Research Report

On December 17, 2013, Santarus, Inc. (Santarus) stock closed at $31.94, and
remained flat as compared to the previous day's closing. The Company's stock
went down 0.03% over the past three trading days, compared to the Dow Jones
Industrial Average which modestly went up by 0.86% during the same trading
period. The Full Research Report on Santarus, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://analystscorner.com/microwriter/link.php?s=DDD

http://www.analystscorner.com/r/full_research_report/22f8_SNTS

Hologic Inc. Research Report

On December 9, 2013, Hologic Inc. (Hologic) announced the appointment of
Stephen P. MacMillan as the Company's President and CEO, and a member of the
Board of Directors. David R. LaVance, Jr., Chairman of the Board. "The Board
unanimously concluded that his track record of delivering strong financial
results and creating shareholder value makes him the ideal chief executive
officer for Hologic. During his tenure, Steve led Stryker Corporation to
strong operating performance, including nearly tripling revenue, and delivered
stock price appreciation that significantly outperformed the S&P 500 index.
Hologic has made progress in reviewing the strategy, leadership and cost
structure of each of its businesses, and the Board is confident that under
Steve's leadership the Company can leverage its strong product platforms to
drive value for shareholders and other key stakeholders." The Full Research
Report on Hologic Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/d132_HOLX

Brookdale Senior Living Inc. Research Report

On December 17, 2013, Brookdale Senior Living Inc. (Brookdale) stock closed at
$26.95, flat as compared to the previous day's closing price. The Company's
stock went up 0.37% over the past three trading days, compared to the Dow
Jones Industrial Average which modestly went up by 0.86% during the same
trading period. The Full Research Report on Brookdale Senior Living Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/fefe_BKD

--

Idenix Pharmaceuticals Inc. Research Report

On December 2, 2013, Idenix Pharmaceuticals Inc. (Idenix) reported that it has
initiated patient enrollment in the phase II HELIX-2 clinical trial, which
will evaluate an all-oral, direct-acting antiviral (DAA) HCV combination
regimen of samatasvir, Idenix's once-daily pan-genotypic NS5A inhibitor,
simeprevir, a once-daily NS3/4A protease inhibitor jointly developed by
Janssen R&D Ireland and Medivir AB, and TMC647055, a once-daily NS5B
non-nucleoside polymerase inhibitor boosted with low-dose ritonavir developed
by Janssen. "We are pleased with the continuing progress of our clinical
program for samatasvir, which will provide additional important information on
the use of this promising compound as part of all-oral HCV combination
regimens," said Doug Mayers, M.D., Chief Medical Officer of Idenix. "With the
advancement of the samatasvir program as well as that of our novel nucleotide
prodrug inhibitor, IDX21437, we anticipate initiating the evaluation of our
own HCV combination regimen in 2014." The Full Research Report on Idenix
Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/c979_IDIX

Biodel Inc. Research Report

On December 17, 2013, Biodel Inc. (Biodel) announced that it has entered a
long-term supply agreement with Becton, Dickinson and Company (BD) for
worldwide exclusive rights to the novel and proprietary BD Uniject SCF™
Disposable Auto-Disable Injection System for the delivery of liquid glucagon
to treat severe hypoglycemia. Dr. Errol De Souza, President and CEO, Biodel,
stated, "We are pleased to achieve another important milestone in our endeavor
to redefine the glucose rescue treatment standard. Adding the BD Uniject SCF™
Disposable Auto-Disable Injection System to our existing pipeline of adult and
pediatric auto-reconstitution devices will enable us to offer a portfolio of
devices to address and expand the underserved glucagon rescue treatment market
by replacing antiquated, difficult, and cumbersome multi-part kits with
simple, convenient, portable therapies that are close at hand when most
urgently needed." The Full Research Report on Biodel Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/80ae_BIOD

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com



SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)